Brett Ullman
Arena Pharmaceuticals, Inc.
21 Papers
225 Citations
Brett Ullman is an academic researcher from Arena Pharmaceuticals, Inc.. The author has contributed to research in topics: Psychosis & Myocardial infarction. The author has an hindex of 10, co-authored 20 publications.
Chat about Author
Papers
Patent
Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Thuy-Anh Tran,Rena Hayashi,Jason B. Ibarra,Brett Ullman,Ning Zou +4 more
- 17 Mar 2009
TL;DR: In this paper, amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH), idiopathic PAH, familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH
33
Patent
Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
Yifeng Xiong,Martin C. Cherrier,Choi Jin Sun Karoline,Peter I. Dosa,Brian M. Smith,Sonja Strah-Pleynet,Brett Ullman,Bradley Teegarden +7 more
- 02 Oct 2007
TL;DR: In this paper, the 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together are discussed. And the present invention relates to certain pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5HT2a serotonin receptor.
27
Patent
SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
Robert M. Jones,Daniel J. Buzard,Sangdon Han,Sun Hee Kim,Juerg Lehmann,Brett Ullman,Moody Jeanne,Xiuwen Zhu,Scott Stirn +8 more
- 22 Jul 2009
TL;DR: In this paper, the S1P1 receptor-associated disorders, such as psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infection or diseases and viral infections or diseases.
26
Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis.
Yifeng Xiong,Bradley Teegarden,Jin-Sun Karoline Choi,Sonja Strah-Pleynet,Marc Decaire,Honnappa Jayakumar,Peter I. Dosa,Martin Casper,Lan Pham,Konrad Feichtinger,Brett Ullman,John W. Adams,Diane Yuskin,John Frazer,Michael Morgan,Abu J.M. Sadeque,Weichao Chen,Robert R. Webb,Daniel T. Connolly,Graeme Semple,Hussien A. Al-Shamma +20 more
TL;DR: A series of phenyl pyrazole inverse agonists optimized for selectivity, aqueous solubility, antiplatelet activity, low hERG activity, and good pharmacokinetic properties are described, resulting in the discovery of 10k (APD791), a potential treatment for arterial thrombosis.
19
Fused tricyclic indoles as S1P1 agonists with robust efficacy in animal models of autoimmune disease
Daniel J. Buzard,Sangdon Han,Luis Lopez,Andrew M. Kawasaki,Moody Jeanne,Lars Thoresen,Brett Ullman,Juerg Lehmann,Imelda Calderon,Xiuwen Zhu,Tawfik Gharbaoui,Dipanjan Sengupta,Krishnan Ashwin M,Yinghong Gao,Jeff Edwards,Jeremy Barden,Michael Morgan,Khawja A. Usmani,Chuan Chen,Abu J.M. Sadeque,Jayant Thatte,Michelle Solomon,Lixia Fu,Kevin Whelan,Ling Liu,Hussien A. Al-Shamma,Joel Gatlin,Minh Le,Charles Xing,Sheryll Espinola,Robert M. Jones +30 more
TL;DR: Two series of fused tricyclic indoles were identified as potent and selective S1P(1) agonists which produced a significant reduction in circulating lymphocytes which translated into robust efficacy in several rodent models of autoimmune disease.
18